Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502Steven M. Devine, Edwin P. Alyea, Kouros Owzar et al.|Journal of Clinical Oncology|2015Cited by 163
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)Stephanie M. Cushman, Andrew B. Nixon, Chen Jiang et al.|Clinical Cancer Research|2014Cited by 87
Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcomaChang‐Lung Lee, David G. Kirsch, Yvonne M. Mowery et al.|JCI Insight|2019Cited by 60
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Andrew B. Nixon, Wei Deng et al.|Clinical Cancer Research|2020Cited by 57
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L. Hertz, Howard L. McLeod, Kouros Owzar et al.|Clinical Cancer Research|2016Cited by 57